A synthetic peptide acting as a triple agonist for GLP-1, GIP, and glucagon receptors, designed for treating obesity and type 2 diabetes by promoting weight loss and glycemic control.
A huge new peptide called retatrutide (12âŻmg once a week) cut body weight by about 27% in clinical trials, beating all other GLPâ1 drugs. Tirzepatide also worked well, but not as dramatically. The study shows that people who start heavier lose more weight, and those with higher blood sugar see bigger glucose improvements.
Novikoff. Aaron A; Grandl. Gerald G; Liu. Xue X; D Müller. Timo T
Retatrutide is a new tripleâacting peptide that hits three gut hormone receptors at once. In early trials it cut body weight by about 25% in roughly half the time it takes the current best drug, tirzepatide, and may even beat the results of gastricâbypass surgery. This shows that nextâgeneration antiâobesity drugs could be dramatically more powerful than what we have now.
In a 36âweek trial with adults who have type 2 diabetes, the experimental peptide retatrutide (especially at 8âŻmg and 12âŻmg weekly doses) made participants feel less hungry, less likely to overeat, and more able to control their eating. These appetite changes were linked to bigger drops in body weight, and the effects were generally stronger than those seen with the existing drug dulaglutide.
Heerspink. Hiddo J L HJL; Lu. Zeqing Z; Du. Yu Y; Duffin. Kevin L KL; Coskun. Tamer T; Haupt. Axel A...
Retatrutide, a tripleâreceptor agonist, lowered urine albumin (a kidney stress marker) and boosted estimated kidney filtration rates in people with obesity (and in those with diabetes at high doses for albumin). The biggest kidney benefits were seen at the 8â12âŻmg doses, especially in nonâdiabetic overweight/obese participants.
A new drug called retatrutide, which hits three hormone receptors (GLPâ1, GIP, and glucagon), cut body weight by about 14% and improved blood sugar, blood pressure, and waist size in obese adults, with sideâeffects similar to a placebo.
The abstract reviews new obesity drugs that combine gut hormones. The newest tripleâhormone combo, retatrutide (GLPâ1, GIP, and glucagon), is in phaseâ3 trials and early data suggest it could cause more weight loss than the current best drug, tirzepatide, possibly approaching the results of bariatric surgery.
Misra. Saurav S; Narayan. Ravi Kant RK; Kaur. Manmeet M
Retatrutide, a peptide that hits three gut hormone receptors, has been shown in several clinical trials to cause strong weight loss and better metabolic health when given as a weekly injection. The 12âŻmg dose worked best, helping people lose 5â20% of their body weight, but it can cause stomach upset.
Tewari. Jay J; Qidwai. Khalid Ahmad KA; Tewari. Ajoy A; Kaur. Savneet S; Tewari. Vineeta V; Maheshwa...
A new drug called retatrutide, which hits three hormone receptors at once, has been tested in four small clinical trials and consistently beat placebo in shrinking weight. The biggest effect was seen with a 12âŻmg dose, and sideâeffects were about the same as taking a dummy pill. While more research is still needed, the early data suggest it could be a powerful tool for people looking to lose fat and improve metabolic health.
Xie. Zeyu Z; Zheng. Guimei G; Liang. Zhuoru Z; Li. Mengting M; Deng. Weishang W; Cao. Weiling W
A big study of 27 trials (15,584 people) shows that the experimental peptide retatrutide can cut body weight by about 20â22% after 16 weeks or more, especially at the 8âŻmg and 12âŻmg doses. It also shrinks waist size by roughly 16â17âŻcm and does this without raising serious sideâeffects or causing low blood sugar. The effect is strongest in people without typeâ2 diabetes, those who start with a higher BMI, and those who stay on the drug longer. Dualâ or tripleâagonist drugs like retatrutide work better for weight loss than plain GLPâ1 drugs.
Tetelbaun. Lauren L; Mullally. Jamie A JA; Frishman. William H WH
Retatrutide is a new experimental drug that hits three hormone receptors (GLPâ1, GIP, and glucagon) and has shown strong weightâloss results in earlyâstage trials. It works with a onceâweekly injection, has a halfâlife of about six days, and its sideâeffects are mainly stomachârelated, similar to other GLPâ1 drugs. Higher doses gave bigger drops in body weight, suggesting it could become a powerful tool for people looking to lose fat and improve metabolic health once itâs approved.
New drugs that mix glucagon and GLPâ1 signals, like retatrutide, are showing big weightâloss and liverâhealth benefits in early trials. They work by boosting metabolism, burning fat, and cutting appetite, while the GLPâ1 part keeps blood sugar in check. The longâterm safety and exact mechanisms are still being studied, but the results look promising for tackling obesity and fattyâliver disease.
Lupianez-Merly. Camille C; Dilmaghani. Saam S; Vosoughi. Kia K; Camilleri. Michael M
This review looks at the newest drugs that help people lose weight, including the alreadyâapproved pills and injections and the nextâgeneration compounds like tirzepatide and retatrutide that are about to hit the market. It explains how these drugs work on hormones that control appetite and metabolism, shows that they can keep people losing weight for a year or more, and points out the main sideâeffects to watch for.
A big review of 55 placeboâcontrolled trials shows that the newest GLPâ1âbased drugs, especially the tripleâagonist retatrutide, can cut far more weight than older medicines. While older drugs like liraglutide lose about 4âŻkg, retatrutide can drop 22â24âŻkg after a year, though itâs still experimental. Sideâeffects are mainly nausea, vomiting, diarrhea and constipation, and the drug works a bit better in younger people.
Locatelli. João Carlos JC; Costa. Juliene Gonçalves JG; Haynes. Andrew A; Naylor. Louise H...
New weightâloss peptides like retatrutide can help you drop 15â24% of body weight, but they also cause a noticeable loss of muscle (about 10% or 6âŻkg). Adding a structured resistanceâtraining program (at least 10 weeks long) can add back roughly 3âŻkg of lean mass and boost strength by ~25%, helping you keep the muscle you lose while still burning fat.
Liu. Song S; Hu. Jiaqiang J; Zhao. Chen C; Liu. Hang H; He. Chunyang C
A big review of 24 trials shows that the new multiâreceptor peptide retatrutide can cut about 12âŻkg (26âŻlb) off body weight in people who are overweight or obese, and it also lowers blood pressure a bit. Its cousin tirzepatide works just as well or a little better for weight loss and drops systolic pressure by roughly 7âŻmmHg. Both drugs lower blood sugar by more than 1% in diabetics, and serious sideâeffects are rare.
A big review of 25 trials found that drugs that activate the GLPâ1 receptor â like liraglutide, semaglutide, tirzepatide and the newer peptide retatrutide â can cut liver fat by about 5% after roughly six months. Retatrutide showed the biggest drop in liver fat, and these drugs also improved liver inflammation and cell damage markers without hurting the liver.
Coskun. Tamer T; Wu. Qiwei Q; Schloot. Nanette C NC; Haupt. Axel A; Milicevic. Zvonko Z; Khouli. Cou...
In a 36âweek trial with people who have type 2 diabetes, the experimental peptide retatrutide cut total body fat by up to about 26% at the highest dose, far more than the standard drug dulaglutide (â2.6%) or placebo (â4.5%). Fat loss grew with higher doses, and the amount of lean muscle lost was similar to other weightâloss treatments. Side effects were mostly mild stomach issues and were similar across groups.
Sanyal. Arun J AJ; Kaplan. Lee M LM; Frias. Juan P JP; Brouwers. Bram B; Wu. Qiwei Q; Thomas. Meliss...
Retatrutide, a new tripleâhormone peptide, cuts liver fat by up to 82% in 24 weeks and drives massive weight loss (around 23â24% at the highest doses). The effect gets bigger with higher doses and is linked to better insulin sensitivity and lower abdominal fat. Itâs still in early trials, but the results are striking for anyone looking to tackle fatty liver and obesity.
A big analysis of 19 trials shows that retatrutide, a tripleâhormone peptide (GLPâ1, GIP, glucagon), can cut about 11âŻkg of weight on average, which is a bit more than the best GLPâ1 drugs (around 9âŻkg). It also makes it far more likely to lose 15% or more of body weight, but it comes with a higher chance of side effects.
Retatrutide, a new drug that hits three hormone receptors (GLPâ1, GIP, and glucagon), helped people lose a lot of weight in a PhaseâŻ2 trial â about 7% at the lowest dose and up to roughly 18% at the highest dose over 24 weeks. The main side effects were typical for this class â nausea, diarrhea and vomiting â and it also raised heart rate by up to 7 beats per minute, which could be a concern. The data look promising for obesity and typeâ2 diabetes, but we still need headâtoâhead comparisons with existing drugs like semaglutide or tirzepatide before it can be recommended for selfâexperimentation.